Drug shows promising results for obese with pre-diabetes

08/24/2011 | Medscape (free registration)

Obese patients with pre-diabetes who took the experimental drug GFT505 had a 24.8% reduction in fasting plasma triglyceride levels, a 9.3% increase in HDL cholesterol and an 8.7% reduction in total cholesterol, a study in Diabetes Care found. The findings suggest that the new compound may help cut the risks of heart disease by decreasing insulin resistance and liver complications in such patients, the lead researcher said.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR